We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.). Coagulation parameters were normal (thrombin time 20 s, aPTT 20 s, INR 1.08) and the patient improved from an NIHSS of 15 to 5 within 24 h with sonographic evidence of M1 recanalization. She did not develop intracranial bleeding complications but showed unusually large diffuse skin ecchymoses. In our report, we give an overview of all reported cases of thrombolysis under dabigatran anticoagulation and discuss the questions of medication adherence under novel oral anticoagulants (NOA) and the safety of NOA in terms of secondary intracerebral hemor...
BACKGROUND AND IMPORTANCE: Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke ...
Oral anticoagulant therapy is recommended for the prevention and treatment of venous thromboembolism...
Introduction. Our study analysed the safety and effectiveness of idarucizumab in enabling intravenou...
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who recei...
Background Aim was to describe the clinical spectrum, therapy, and outcome of ischemic strokes under...
Journal ArticleDabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thro...
OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIE...
Dabigatran, marketed as Pradaxa (Boehringer Ingelheim) in the USA, is a direct thrombin inhibitor th...
Abstract Background Non-vitamin K antagonist oral anticoagulants, including dabigatran, are currentl...
Objective: To describe the benefits of reversal of the anticoagulation effects of dabigatran etexila...
Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalv...
Copyright © 2015 Priyank Shah et al. This is an open access article distributed under the Creative C...
We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery f...
Abstract Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. hepa...
Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation...
BACKGROUND AND IMPORTANCE: Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke ...
Oral anticoagulant therapy is recommended for the prevention and treatment of venous thromboembolism...
Introduction. Our study analysed the safety and effectiveness of idarucizumab in enabling intravenou...
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who recei...
Background Aim was to describe the clinical spectrum, therapy, and outcome of ischemic strokes under...
Journal ArticleDabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thro...
OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIE...
Dabigatran, marketed as Pradaxa (Boehringer Ingelheim) in the USA, is a direct thrombin inhibitor th...
Abstract Background Non-vitamin K antagonist oral anticoagulants, including dabigatran, are currentl...
Objective: To describe the benefits of reversal of the anticoagulation effects of dabigatran etexila...
Dabigatran is a direct thrombin inhibitor used to reduce the risk of stroke in patients with nonvalv...
Copyright © 2015 Priyank Shah et al. This is an open access article distributed under the Creative C...
We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery f...
Abstract Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. hepa...
Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation...
BACKGROUND AND IMPORTANCE: Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke ...
Oral anticoagulant therapy is recommended for the prevention and treatment of venous thromboembolism...
Introduction. Our study analysed the safety and effectiveness of idarucizumab in enabling intravenou...